Edwards Lifesciences (EW) Has a Growth Runway Competitors May Struggle to Match

3 weeks ago 27

Soumya Eswaran

Tue, August 4, 2026 astatine 10:17 AM CDT 3 min read

Baron Capital, an concern absorption company, released its Q2 2026 capitalist missive for the "Baron Health Care Fund". A transcript of the missive is disposable to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% summation for the Russell 3000 Health Care Index and the 15.44% summation for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% connected an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong banal enactment successful pharmaceuticals, biotechnology, wellness attraction equipment, and beingness sciences tools and services supported the Fund's outperformance, though constricted vulnerability to managed attraction stocks reduced comparative returns. The Fund remains affirmative connected wellness attraction owed to improving biotechnology funding, beardown acquisition activity, recovering managed attraction margins, and maturation from an aging population, chronic disease, aesculapian innovation, and higher wellness attraction spending. In addition, delight cheque the Fund's apical 5 holdings to cognize the champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Baron Health Care Fund highlighted Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) is simply a aesculapian exertion institution that provides products and technologies to dainty precocious cardiovascular diseases. On August 3, 2026, Edwards Lifesciences Corporation (NYSE:EW) closed astatine $88.82 per share. The one-month instrumentality of Edwards Lifesciences Corporation (NYSE:EW) was -6.33% and its shares gained 12.09% implicit the past 52 weeks. Edwards Lifesciences Corporation (NYSE:EW) has a marketplace capitalization of $51.14 billion.

Baron Health Care Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its Q2 2026 capitalist letter:

"Edwards Lifesciences Corporation (NYSE:EW) was a worldly tailwind successful the period. Shares of Edwards, a aesculapian exertion institution specializing successful structural bosom illness therapies, roseate owed to coagulated archetypal 4th results and an updated Medicare sum determination for transcatheter aortic valve replacement (TAVR), which has the imaginable to summation process volumes. We retain conviction arsenic Edwards' pb successful replacement therapies for mitral and tricuspid valves, which combined with a full addressable marketplace that could attack the standard of halfway TAVR provides a durable and differentiated maturation runway that competitors are years distant from replicating."

Jim Cramer Notes Edwards Lifesciences (EW) is successful a "Good Zone"

Edwards Lifesciences Corporation (NYSE:EW) is not on our database of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 68 hedge money portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the extremity of the first quarter which was 64 in the erstwhile quarter. While we admit the imaginable of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that also stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article